Related Experiment Video
Updated: May 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme
Alvin R Cabrera1, Kyle C Cuneo, James J Vredenburgh
1Department of Radiation Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. alvin.cabrera@duke.edu
Abstract:
Despite contemporary surgery, image-guided radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) persists or relapses in nearly all patients, and tumors almost always recur locally. Management of recurrent GBM is variable, but approaches include best supportive care, reoperation, reirradiation, and/or systemic therapy. Promising novel therapies include antiangiogenic agents and stereotactic radiosurgery, which have cytotoxic effects on tumor microvasculature. Emerging data suggest the safety and efficacy of bevacizumab and radiosurgery either alone or in combination. This report presents the case of a man with locally recurrent GBM treated with stereotactic radiosurgery and concurrent bevacizumab, and reviews the preclinical and clinical data supporting this approach.

